Skip to main content

Table 2 Sensitivity and specificity of cytology, hrHPV, HPV16/18 genotyping and DNA methylation for detecting CIN3+ 

From: Performance of DNA methylation analysis in the detection of high-grade cervical intraepithelial neoplasia or worse (CIN3+): a cross-sectional study

 

Sensitivity

Specificity

AUCb

 

95% CI

95% CI

95% CI

Cytology

71.4% (42.0–90.4%)

78.3% (65.4–87.5%)

0.749 (0.598–0.900)

hrHPV

92.9% (64.2–99.6%)

76.7% (63.7–86.2%)

0.848 (0.744–0.952)

HPV16/18

50.0% (24.0–76.0%)

95.0% (85.2–98.7%)

0.725 (0.55–0.898)

Methylation markersa

   

miR124-2m

JAM3m

LOC100289333m

ZIC1m

SOX1m

64.3% (35.6–86.0%)

50.0% (24.0–76.0%)

85.7% (56.2–97.5%)

78.6% (48.8–94.3%)

85.7% (56.2–97.5%)

88.3% (76.8–94.8%)

100.0% (92.5–100.0%)

86.7% (74.9–93.7%)

88.3% (76.8–94.8%)

90.0% (78.8–95.9%)

0.763 (0.605–0.922)

0.750 (0.576–0.924)

0.862 (0.744–0.980)

0.835 (0.700–0.969)

0.879 (0.763–0.994)

  1. aUsing a threshold for positivity at a methylation ratio of 8.56 for MIR124-2, 5.94 for JAM3, 6.27 for LOC100289333, 3.29 for ZIC1, and 5.25 for SOX1
  2. bThe performance of each marker in cervical scrapes was evaluated by AUC with 95% (CI)